Henlius Wins Australian Nod to Start First-in-Class Trispecific Antibody Trial for Advanced Prostate Cancer

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.

Shanghai Henlius Biotech has received clearance in Australia to begin a phase 1 clinical trial of HLX3902, a trispecific STEAP1×CD3×CD28 T-cell engager antibody, for metastatic castration-resistant prostate cancer and other advanced solid tumors. The candidate is designed to redirect and amplify cytotoxic T-cell activity against STEAP1-expressing tumors, and preclinical data suggest promising anti-tumor efficacy and safety, positioning Henlius at the forefront of a modality for which no STEAP1-CD3-CD28 trispecific antibody has yet been approved worldwide.

The Australian regulatory and ethics approvals mark an important step in Henlius’s efforts to globalize its R&D and expand its oncology pipeline into high-need indications. While the company cautions that successful development and commercialization are not guaranteed, this trial underscores Henlius’s ambition to compete in cutting-edge immuno-oncology and could enhance its standing among investors and partners if clinical benefits are confirmed.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing innovative antibody therapies. Its pipeline includes biologic drugs and novel multispecific antibodies targeting oncology indications, with an eye on both domestic and international markets.

Average Trading Volume: 929,524

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$38.67B

For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.